Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)
Express News | DiaMedica Therapeutics Inc - Top-Line Results for Part 1a Expected in H1 2025
Express News | DiaMedica Therapeutics Inc - Dosing to Begin in Q4 2024, Results Expected H1 2025
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Express News | DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of Dm199 in the Treatment of Preeclampsia
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Diamedica Therapeutics Initiated at Buy by HC Wainwright & Co.
H.C. Wainwright Initiates DiaMedica Therapeutics(DMAC.US) With Buy Rating, Announces Target Price $7
Optimistic Outlook on DiaMedica Therapeutics' Market Potential and Clinical Advancements
DiaMedica Therapeutics Upcoming Conference Participation
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target
DiaMedica Therapeutics Analyst Ratings
Earnings Call Summary | DiaMedica Therapeutics(DMAC.US) Q2 2024 Earnings Conference
Express News | DiaMedica Reiterates Its Guidance That Full Enrollment For The 144 Patients For The Interim Analysis Will Be Completed In The First Quarter Of 2025